Notice of Board of Director and Corporate Auditor Nominations

May 11, 2023, Osaka, Japan - Santen Pharmaceutical Co., Ltd. (hereinafter “Santen”) announced today the nominations for the members of the Board of Directors and Corporate Auditors effective June 27, 2023, subject to approval at the 111th Annual General Meeting of Shareholders and the following Board of Directors meeting on June 27, 2023.

Members of the Board of Directors (As of June 27, 2023)

[Directors]

	Name	New position	Current position
Reappointed	Akira Kurokawa	Representative Director of the Board, Chairman	Representative Director of the Board, Chairman
	Takeshi Ito	Representative Director of the Board, President, Chief Executive Officer	Representative Director of the Board, President, Chief Executive Officer
	Kanoko Oishi	Member of the Board*	Member of the Board*
	Yutaro Shintaku	Member of the Board*	Member of the Board*
	Kunihito Minakawa	Member of the Board*	Member of the Board*
	Noboru Kotani	Member of the Board*	Member of the Board*
	Tamie Minami	Member of the Board*	Member of the Board*

*Outside Directors are independent officers as designated by the Tokyo Stock Exchange.

[Corporate Auditors]

	Name	New position	Current position
Newly appointed	Junichi Asatani	Corporate Auditor**	---
Newly appointed	Yaeko Hodaka	Corporate Auditor**	---
Retirement	Hirofumi Yasuhara	---	Corporate Auditor**
Retirement	Yumiko Ito	---	Corporate Auditor**

**Outside Corporate Auditors are independent officers designated by the Tokyo Stock Exchange.

Other Corporate Auditors (Hiroshi Isaka, Masahiko Ikaga) are within their tenure, not subjects for reelection this year.

About Santen
As a specialized company dedicated to eye health, Santen carries out research, development, marketing, and sales of pharmaceuticals, over-the-counter products, and medical devices, and its products now reach patients in over 60 countries and regions. Toward realizing “WORLD VISION” (Happiness with Vision), the world Santen ultimately aspires to achieve, as a “Social Innovator”, Santen aims to reduce the social and economic opportunity loss of people around the world caused by eye diseases and defects by orchestrating and mobilizing key technologies and players around the world. With scientific knowledge and organizational capabilities nurtured over a 130-year history, Santen provides products and services to contribute to the well-being of patients, their loved ones and consequently to society.
For more information, please visit Santen’s website (https://www.santen.com/en).

Contact
Corporate Communications
Santen Pharmaceutical Co., Ltd.
E-mail: communication@santen.com

Official SNS